{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:12:20Z","timestamp":1776265940793,"version":"3.50.1"},"reference-count":39,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"4","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: To explore the value of the serum levels of macrophage inhibitory factor 1 (MIC-1), lemur tyrosine kinase 3 (LMTK-3), and insulin-like growth factor binding protein 7 (IGFBP-7) in the prognosis assessment of patients with advanced lung cancer treated with ablation combined with chemotherapy. Methods: 190 patients with advanced lung cancer who received care at this hospital between January 2022 and June 2024 were chosen to be part of the lung cancer group. The healthy control group consisted of 90 healthy individuals who attended the hospital and underwent physical tests during the same time period. Percutaneous microwave thermal ablation treatment was used to treat every patient with advanced lung cancer, and chemotherapy was administered within one week after treatment. The levels of serum MIC-1, LMTK-3, and IGFBP-7 before and after treatment, and before treatment, were compared between patients with different therapeutic effects in the lung cancer group and the healthy control group. Univariate and multivariate analyses were conducted to examine the factors affecting patient prognosis and the efficacy of serum MIC-1, LMTK-3, and IGFBP-7 levels in predicting patient prognosis in patients with advanced lung cancer. Results: Serum MIC-1 and LMTK-3 levels in the lung cancer group were substantially higher than those in the healthy control group both before and after therapy (P&amp;lt;0,05). Serum MIC-1 and LMTK-3 levels in the lung cancer group were significantly lower after therapy than before (P&amp;lt;0,05). The serum IGFBP-7 levels in the lung cancer group before and after treatment were significantly lower than those in the healthy control group (P&amp;lt;0,05). After treatment, the serum IGFBP-7 level in the lung cancer group was significantly higher than before treatment (P&amp;lt;0,05). Patients with lung cancer experienced 29 cases of stable response (SD)+ progressive response (PD) and 66 cases of complete response (CR)+ partial response (PR) following treatment. Those with SD + PD advanced lung cancer had significantly higher blood MIC-1 and LMTK-3 levels before treatment than those with CR+PR advanced lung cancer. The serum IGFBP-7 level of advanced lung cancer patients with SD+PD before treatment was significantly lower than that of advanced lung cancer patients with CR+PR. In patients with advanced lung cancer, elevated blood MIC-1 and LMTK-3 levels and lower IGFBP-7 levels before treatment were independent risk factors for death within a year following treatment (P&amp;lt;0,05). The combined detection of serum MIC-1, LMTK-3, and IGFBP-7 levels for predicting death within 1 year after treatment for advanced lung cancer had a sensitivity of 91.3%, a specificity of 95.8%, and an AUC of 0.974. Its AUC was significantly greater than that of MIC-1 (Z=2.378, P=0.017) and LMTK-3 (Z=2.897). The AUC was separately assessed for IGFBP-7 (Z=3.213, P=0.001). However, the AUCs for the three indicators did not differ significantly (P&amp;gt;0.05). Conclusions: Important markers for assessing the effectiveness of chemotherapy and ablation in the treatment of advanced lung cancer are serum MIC-1, LMTK-3, and IGFBP-7. With the help of combination detection, the prognosis of patients with advanced lung cancer after therapy can be predicted.<\/jats:p>","DOI":"10.5937\/jomb0-62184","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:40:57Z","timestamp":1763541657000},"page":"856-864","source":"Crossref","is-referenced-by-count":0,"title":["Serum MIC-1, LMTK-3 and IGFBP-7 levels in the prognosis of lung cancer treated with ablation combined with chemotherapy"],"prefix":"10.5937","volume":"45","author":[{"given":"Yilin","family":"Fu","sequence":"first","affiliation":[{"name":"Shandong Provincial Hospital Affiliated to Shandong First Medical University, Department of Thoracic Surgery, Jinan City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifeng","family":"Shi","sequence":"additional","affiliation":[{"name":"Shandong First Medical University, Jinan City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanxin","family":"Lu","sequence":"additional","affiliation":[{"name":"Shandong First Medical University, Jinan City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatao","family":"Yu","sequence":"additional","affiliation":[{"name":"Shandong First Medical University, Jinan City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xiaofeng","sequence":"additional","affiliation":[{"name":"Anhui Provincial Hospital, Department of Oncology, Hefei City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Guoliang","sequence":"additional","affiliation":[{"name":"Anhui Provincial Hospital, Department of Oncology, Hefei City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Provincial Hospital Affiliated to Shandong First Medical University, Department of Thoracic Surgery, Jinan City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"#cr-split#-ref1.1","doi-asserted-by":"crossref","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Janne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small cell lung cancer. Lancet 2024 Aug 24","DOI":"10.1016\/S0140-6736(24)01029-8"},{"key":"#cr-split#-ref1.2","doi-asserted-by":"crossref","unstructured":"404(10454): 803-22. doi: 10.1016\/S0140-6736(24)01029-8. Epub 2024 Aug 6. PMID: 39121882;","DOI":"10.1016\/S0140-6736(24)01029-8"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Greer JA, Post KE, Chabria R, Aribindi S, Brennan N, Eche-Ugwu IJ, Halpenny B, Fox E, Lo S, Waldman LP, Pintro K, Rabideau DJ, Pirl WF, Cooley ME, Temel JS. Randomised Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer. J Clin Oncol 2024 Oct 20; 42(30): 3570-80. doi: 10.1200\/JC0.24.00048. Epub 2024 Aug 1. PMID: 39088766; PMCID: PMC11483213;","DOI":"10.1200\/JCO.24.00048"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, Puri S, Naqash AR. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol 2024 Aug; 21(8): 610-27. doi: 10.1038\/s41571-024-00914-x. Epub 2024 Jul 4. PMID: 38965396; PMCID: PMC1187502;","DOI":"10.1038\/s41571-024-00914-x"},{"key":"ref4","unstructured":"Reuss JE, Rosner S, Levy BP. Antibody drug conjugates in advanced lung cancer: Is this a new frontier? Clin Adv Hematol Oncol 2024 Jun; 22(5): 217-26. PMID: 38805313;"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wu L, Li X, Yan J. Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol 2024 Jul; 45: 101995. doi: 10.1016\/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241;","DOI":"10.1016\/j.tranon.2024.101995"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Xue H, Chen Y, Zhou Y. Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer. Front Immunol 2024 Dec 6; 15: 1522508. doi: 10.3389\/fimmu.2024.1522508. PMID: 39712010; PMCID: PMC11659256;","DOI":"10.3389\/fimmu.2024.1522508"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Loh J, Low JL, Sachdeva M, Low PQ, Wong RSJ, Huang Y, Chia PL, Soo RA. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer. Expert Rev Anticancer Ther 2023 Jul-Dec; 23(9): 913-26. doi: 10.1080\/14737140.2023.2245140. Epub 2023 Aug 13. PMID: 37551698;","DOI":"10.1080\/14737140.2023.2245140"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Solta A, Ernhofer B, Boettiger K, Megyesfalvi Z, Heeke S, Hoda MA, Lang C, Aigner C, Hirsch FR, Schelch K, D\u00f4me B. Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer. Mol Cancer 2024 Feb 24; 23(1): 41. doi: 10.1186\/s12943-024-01953-9. PMID: 38395864; PMCID: PMC10893629;","DOI":"10.1186\/s12943-024-01953-9"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Tsukada A, Morita C, Shimizu Y, Uemura Y, Naka G, Takasaki J, Nokihara H, Izumi S, Hojo M. Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis. Thorac Cancer 2024 Sep; 15(25): 1854-62. doi: 10.1111\/1759-7714.15413. Epub 2024 Jul 31. PMID: 39086088; PMCID: PMC11367661;","DOI":"10.1111\/1759-7714.15413"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Wu L, Yang L, Qian X, Hu W, Wang S, Yan J. Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment. J Funct Biomater 2024 Aug 16; 15(8): 229. doi: 10.3390\/jfb15080229. PMID: 39194667; PMCID: PMC11355305;","DOI":"10.3390\/jfb15080229"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Yu L, Wang R, Zhao Y, Wu Y, Wang L, Chen H, He Z, Wang Q, Wu Y. Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Non-small Cell Lung Cancer. Technol Cancer Res Treat 2023 Jan-Dec; 22: 15330338231168466. doi: 10.1177\/15330338231168466. PMID: 37078129; PMCID: PMC10126640;","DOI":"10.1177\/15330338231168466"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV\/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY) 2021 Apr 20; 13(8): 10833-52. doi: 10.18632\/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137;","DOI":"10.18632\/aging.202860"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kundu M, Dey A, Dasgupta S. Replication stress response and radioresistance in lung cancer: Mechanistic insights and advanced therapeutic approaches. Curr Probl Cancer 2025 Jun; 56: 101206. doi: 10.1016\/j.currproblcancer.2025.101206. Epub 2025 Apr 22. PMID: 40267631;","DOI":"10.1016\/j.currproblcancer.2025.101206"},{"key":"#cr-split#-ref14.1","doi-asserted-by":"crossref","unstructured":"Melosky B, Vincent MD, McGuire AL, Brade AM, Chu Q, Cheema P, Martins I, Spicer JD, Snow S, Juergens RA. Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer. Int J Cancer 2024 Sep 15","DOI":"10.1002\/ijc.35031"},{"key":"#cr-split#-ref14.2","doi-asserted-by":"crossref","unstructured":"155(6): 963-78. doi: 10.1002\/ijc.35031. Epub 2024 Jun 20. PMID: 38900018;","DOI":"10.1002\/ijc.35031"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lee S, Park S, Lee HY, Jeon H, Lee S, Choi S, Eo W. A potential treatment option for advanced non-small cell lung cancer: Three cases. Explore (NY) 2023 May-Jun; 19(3): 453-7. doi: 10.1016\/j.explore.2022.04.001. Epub 2022 Apr 5. PMID: 35431108;","DOI":"10.1016\/j.explore.2022.04.001"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines 2022 Sep 10; 10(9): 2248. doi: 10.3390\/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572;","DOI":"10.3390\/biomedicines10092248"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Gridelli C, Attili I, Bennati C, Bironzo P, Bria E, Cortinovis DL, Soto Parra H, de Marinis F. Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results? Lung Cancer 2025 Apr; 202: 108482. doi: 10.1016\/j.lungcan.2025.108482. Epub 2025 Mar 7. PMID: 40086027;","DOI":"10.1016\/j.lungcan.2025.108482"},{"key":"#cr-split#-ref18.1","unstructured":"Simone CB 2nd. Enhancing Outcomes in Locally Advanced Non-Small Cell Lung Cancer Through Stereotactic Dose Escalation. Int J Radiat Oncol Biol Phys 2024 Nov 1"},{"key":"#cr-split#-ref18.2","doi-asserted-by":"crossref","unstructured":"120(3): 695-7. doi: 10.1016\/j.ijrobp.2024.06.036. Epub 2024 Sep 24. PMID: 39326955;","DOI":"10.1016\/j.ijrobp.2024.06.036"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Buma AIG, Schuurbiers MMF, van Rossum HH, van den Heuvel MM. Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer. Tumor Biol 2024; 46(s1): S207-S217. doi: 10.3233\/TUB-220034. PMID: 36710691;","DOI":"10.3233\/TUB-220034"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines 2023 Jun 29; 11(7): 1861. doi: 10.3390\/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220;","DOI":"10.3390\/biomedicines11071861"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Opalikhin A, Friedland S, Madariaga ML, Owen DH, Besse B. Surgical and Perioperative Advances for Patients With Locally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book 2025 Jun; 45(3): e481060. doi: 10.1200\/EDBK-25-481060. Epub 2025 Jun 12. PMID: 40505076;","DOI":"10.1200\/EDBK-25-481060"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lobinger D, Hiebinger A, Eicher F, GroB G, Shalabi I, Reiche A, Bodner J. Rescue surgery in palliative indication as last therapeutic option for complicated advanced stage lung cancer. Eur J Surg Oncol 2023 Dec; 49(12): 107253. doi: 10.1016\/j.ejso.2023.107253. Epub 2023 Oct 31. PMID: 37944369;","DOI":"10.1016\/j.ejso.2023.107253"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs 2022 Jan 1; 33(1): e590-e603. doi: 10.1097\/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349;","DOI":"10.1097\/CAD.0000000000001189"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Khan SR, Breadner D. Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small Cell Lung Cancer Treatment. Curr Oncol 2025 Mar 31; 32(4): 206. doi: 10.3390\/curroncol32040206. PMID: 40277763; PMCID: PMC12025875;","DOI":"10.3390\/curroncol32040206"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kearns E, Chu AK, Nissim R, Wheatley-Price P, Aubry T, Lebel S. The Supportive Care Needs of Individuals Living With Advanced or Metastatic Lung Cancer Receiving Targeted or Immunotherapies. Psychooncology 2024 Nov; 33(11): e70015. doi: 10.1002\/pon.70015. PMID: 39472304;","DOI":"10.1002\/pon.70015"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs 2022 Oct 1; 33(9): 943-59. doi: 10.1097\/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295;","DOI":"10.1097\/CAD.0000000000001319"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Durbin L, Murali B, Li S, Hawthorne S, Clark O. Treatment patterns in advanced\/metastatic non-small cell lung cancer in China: results from the Cancer-MPact\u00ae survey 2021. Future Oncol 2024; 20(19): 1319-31. doi: 10.2217\/fon-2023-0469. Epub 2024 May 2. PMID: 38695478; PMCID: PMC11321399;","DOI":"10.2217\/fon-2023-0469"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Gautam Roy P, Reingold D, Pathak N, Verma S, Gupta A, Meti N, Molto C, Malik PS, Linford G, Mittal A. Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer-A Narrative Review. Curr Oncol 2025 Aug 9; 32(8): 448. doi: 10.3390\/curroncol32080448. PMID: 40862817; PMCID: PMC12384734;","DOI":"10.3390\/curroncol32080448"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting 2024; 10(1): 1256. doi: 10.36922\/ijb.1256;","DOI":"10.36922\/ijb.1256"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zhang YR, Lu YH, Lin CM, Ku JW. Pretreatment CT Texture Analysis for Predicting Survival Outcomes in Advanced Non-small Cell Lung Cancer Patients Receiving Immunotherapy: A Systematic Review and Meta-Analysis. Thorac Cancer 2025 Aug; 16(15): e70144. doi: 10.1111\/1759-7714.70144. PMID: 40755255; PMCID: PMC12320133;","DOI":"10.1111\/1759-7714.70144"},{"key":"ref31","unstructured":"Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care. Saudi Med J 2024 Oct; 45(10): 1200. PMID: 39379112; PMCID: PMC11463563;"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel) 2024 Feb 12; 12(2): 186. doi: 10.3390\/vaccines12020186. PMID: 38400169; PMCID: PMC10891594;","DOI":"10.3390\/vaccines12020186"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Roberts HN, Solomon B, Harden S, Lingaratnam S, Alexander M. Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer. Clin Lung Cancer 2024 Jul; 25(5): e211-e220.e1. doi: 10.1016\/j.cllc.2024.04.001. Epub 2024 Apr 6. PMID: 38772809;","DOI":"10.1016\/j.cllc.2024.04.001"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Moretti M, Wellekens S, Dirkx S, Vekens K, Van Laethem J, Ilsen B, Vanderhelst E. Features of postobstructive pneumonia in advanced lung cancer patients, a large retrospective cohort. Infect Dis (Lond) 2023 Feb; 55(2): 149-57. doi: 10.1080\/23744235.2022.2143888. Epub 2022 Nov 11. PMID: 36369872;","DOI":"10.1080\/23744235.2022.2143888"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Chen SY, Wang CT, Huang TH, Tsai JL, Wang HT, Yen YT, Tseng YL, Wu CL, Chang JM, Shiau AL. Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin. Cells 2024 Sep 23; 13(18): 1597. doi: 10.3390\/cells13181597. PMID: 39329778; PMCID: PMC11430802;","DOI":"10.3390\/cells13181597"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sato S, Sezaki R, Shinohara H. Significance of preoperative evaluation of modified advanced lung cancer inflammation index for patients with resectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2024 Aug; 72(8): 527-534. doi: 10.1007\/s11748-023-02003-9. Epub 2024 Jan 22. PMID: 38246904;","DOI":"10.1007\/s11748-023-02003-9"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Nivoi seruma MIC-1, LMTK-3 i IGFBP-7 u prognozi plu\u0107nog karcinoma le\u010denog ablacijom u kombinaciji sa hemoterapijom"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/62184\/29327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582604856F.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:17:06Z","timestamp":1776262626000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582604856F"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-62184","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}